비만 : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Obesity Market Outlook

Thelansis's "Global Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Obesity Overview

Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of numerous comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance-calories consumed exceeding calories expended-being the central driver. Diagnosis is commonly based on body mass index (BMI), with obesity defined as a BMI of 30 or higher, though waist circumference and body composition measures provide additional insight into cardiometabolic risk. Clinical manifestations extend beyond physical health, as obesity is also associated with reduced quality of life, stigma, and psychological distress. Management requires a multifaceted approach combining lifestyle modification, nutritional counseling, physical activity, behavioral therapy, pharmacotherapy, and, in severe cases, bariatric surgery. Despite advances in treatment, obesity remains a global public health challenge, underscoring the need for prevention strategies, long-term care models, and personalized interventions.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Hanmi Pharmaceutical Company Limited
• Tonghua Dongbao Pharmaceutical Co.,Ltd
• Aphaia Pharma US LLC
• NeuroBiogen Co., Ltd
• Eli Lilly and Company
• MindRank AI Ltd
• Pfizer
• Kailera
• Glyscend, Inc.
• NodThera Limited
• Palatin Technologies, Inc
• BrightGene Bio-Medical Technology Co., Ltd.
• Aardvark Therapeutics, Inc.
• Alnylam Pharmaceuticals
• Guangdong Raynovent Biotech Co., Ltd
• Innovent Biologics (Suzhou) Co. Ltd.
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Fujian Shengdi Pharmaceutical Co., Ltd.
• Arrowhead Pharmaceuticals
• Hudson Biotech
• Zomagen Biosciences Ltd.
• Corxel Pharmaceuticals
• Regeneron Pharmaceuticals
• Regor Pharmaceuticals Inc.
• Boehringer Ingelheim
• Novo Nordisk A/S
• Skye Bioscience, Inc.
• Shionogi
• Amgen
• Rhythm Pharmaceuticals, Inc.
• Vanda Pharmaceuticals
• Kallyope Inc.
• Metsera, a wholly owned subsidiary of Pfizer
• S1 Biopharma, Inc.
• Biophytis
• AstraZeneca
• Shandong Suncadia Medicine Co., Ltd.
• Biohaven Therapeutics Ltd.
• Beijing QL Biopharmaceutical Co.,Ltd
• Rose Pharma Inc
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Vincentage Pharma Co., Ltd
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• Gan and Lee Pharmaceuticals, USA
• Verdiva Bio Dev Limited
• Gan & Lee Pharmaceuticals.
• Carmot Therapeutics, Inc.
• Exerkine Corporation
• Terns, Inc.
• Chendu DIAO Pharmaceutical Group CO., LTD.
• Hangzhou Sciwind Biosciences Co., Ltd.
• The United Bio-Technology (Hengqin) Co., Ltd.
• Scholar Rock, Inc.
• Biomed Industries, Inc.
• Ikaria Bioscience Pty Ltd
• Hoffmann-La Roche
• HK inno.N Corporation
• Actimed Therapeutics Ltd
• Inversago Pharma Inc.
• Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
• Immunwork, Inc.
• Veru Inc.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Neuraly, Inc.
• ARKAY Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)